Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer

Executive Summary

The combination of Opdivo and Yervoy showed a survival advantage in renal cancer in a Phase III trial, adding to the understanding that overall survival may be a better endpoint than progression-free survival for measuring immuno-oncology drugs.


Related Content

A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer
Pfizer v. Pfizer: Sutent Indication Expansion Will Hinge On Conflicting Trials
Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts